Anzeige
Mehr »
Login
Mittwoch, 21.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
East Africa Metals: Endlich! Ist das der Startschuss?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 855526 ISIN: JP3160400002 Ticker-Symbol: EII 
Tradegate
21.04.21
09:10 Uhr
55,50 Euro
-1,00
-1,77 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
EISAI CO LTD Chart 1 Jahr
5-Tage-Chart
EISAI CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
55,0056,0009:08
55,5056,0009:37

Aktuelle News zur EISAI Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
EISAI Aktie jetzt für 0€ handeln
DiBiogen/Eisai's lecanemab shows mixed results in mid-stage Alzheimer's Disease study24
DiEisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease220Published in Peer-Reviewed Journal, Alzheimer's Research and TherapyLecanemab Phase 3 Clarity AD Clinical Trial Completed EnrollmentTOKYO, Apr 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen...
► Artikel lesen
14.04.Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting145TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril...
► Artikel lesen
12.04.Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021178TOKYO, Apr 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis...
► Artikel lesen
01.04.FDA advisers reiterate case against approval of Biogen/Eisai's aducanumab for Alzheimer's42
31.03.KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries222TOKYO, Mar 31, 2021 - (JCN Newswire) - KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution...
► Artikel lesen
31.03.Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan197TOKYO, Mar 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today that...
► Artikel lesen
30.03.Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab251As a Treatment for Advanced Renal Cell Carcinoma and Advanced Endometrial CarcinomaTOKYO, Mar 30, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has...
► Artikel lesen
26.03.Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021305TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist...
► Artikel lesen
23.03.Eisai plans drug delivery center to support biologics expansion2
22.03.Eisai Begins Construction of New Injection/Research Building2
22.03.Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan235TOKYO, Mar 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted...
► Artikel lesen
22.03.Eisai Awarded The New Diversity Management Selection 100310TOKYO, Mar 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity...
► Artikel lesen
19.03.Merck, Eisai detail Keytruda and Lenvima's endometrial cancer win in confirmatory study4
19.03.Merck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo5
17.03.DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders348TOKYO, Mar 17, 2021 - (JCN Newswire) - Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement...
► Artikel lesen
16.03.Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu249TOKYO, Mar 16, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and...
► Artikel lesen
15.03.BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021261STOCKHOLM, March 15, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the company...
► Artikel lesen
05.03.Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease318TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß)...
► Artikel lesen
04.03.Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya483TOKYO, Mar 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company...
► Artikel lesen
Seite:  Weiter >>
108 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1